| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles
|
Peetla, Chiranjeevi
|
|
2013
|
136-137 |
13-14 |
p. 1686-1698
13 p.
|
artikel
|
| 2 |
Can nanomedicines kill cancer stem cells?
|
Zhao, Yi
|
|
2013
|
136-137 |
13-14 |
p. 1763-1783
21 p.
|
artikel
|
| 3 |
Clinical implications of mitochondrial disease
|
Muravchick, Stanley
|
|
2008
|
136-137 |
13-14 |
p. 1553-1560
8 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2013
|
136-137 |
13-14 |
p. ii-
1 p.
|
artikel
|
| 5 |
Editorial Board
|
|
|
2008
|
136-137 |
13-14 |
p. ii-
1 p.
|
artikel
|
| 6 |
Estrogen regulation of glucose metabolism and mitochondrial function: Therapeutic implications for prevention of Alzheimer's disease
|
Brinton, Roberta Diaz
|
|
2008
|
136-137 |
13-14 |
p. 1504-1511
8 p.
|
artikel
|
| 7 |
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
|
Kirtane, Ameya R.
|
|
2013
|
136-137 |
13-14 |
p. 1731-1747
17 p.
|
artikel
|
| 8 |
Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease
|
Maczurek, Annette
|
|
2008
|
136-137 |
13-14 |
p. 1463-1470
8 p.
|
artikel
|
| 9 |
Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases
|
Yamada, Yuma
|
|
2008
|
136-137 |
13-14 |
p. 1439-1462
24 p.
|
artikel
|
| 10 |
Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: Mitochondrial targeted preconditioning
|
Busija, David W.
|
|
2008
|
136-137 |
13-14 |
p. 1471-1477
7 p.
|
artikel
|
| 11 |
Mitochondrial medicine and mitochondrion-based therapeutics
|
Hamm-Alvarez, Sarah
|
|
2008
|
136-137 |
13-14 |
p. 1437-1438
2 p.
|
artikel
|
| 12 |
Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants
|
Navarro, Ana
|
|
2008
|
136-137 |
13-14 |
p. 1534-1544
11 p.
|
artikel
|
| 13 |
Mitochondrial trifunctional protein defects: Clinical implications and therapeutic approaches
|
Rector, R. Scott
|
|
2008
|
136-137 |
13-14 |
p. 1488-1496
9 p.
|
artikel
|
| 14 |
Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stress
|
Murray, James
|
|
2008
|
136-137 |
13-14 |
p. 1497-1503
7 p.
|
artikel
|
| 15 |
Monoamine oxidase inactivation: From pathophysiology to therapeutics
|
Bortolato, Marco
|
|
2008
|
136-137 |
13-14 |
p. 1527-1533
7 p.
|
artikel
|
| 16 |
Multidrug resistance: Physiological principles and nanomedical solutions
|
Kunjachan, Sijumon
|
|
2013
|
136-137 |
13-14 |
p. 1852-1865
14 p.
|
artikel
|
| 17 |
Nanocarriers for delivery of platinum anticancer drugs
|
Oberoi, Hardeep S.
|
|
2013
|
136-137 |
13-14 |
p. 1667-1685
19 p.
|
artikel
|
| 18 |
Nanomedicine therapeutic approaches to overcome cancer drug resistance
|
Markman, Janet L.
|
|
2013
|
136-137 |
13-14 |
p. 1866-1879
14 p.
|
artikel
|
| 19 |
Nanopreparations to overcome multidrug resistance in cancer
|
Patel, Niravkumar R.
|
|
2013
|
136-137 |
13-14 |
p. 1748-1762
15 p.
|
artikel
|
| 20 |
Nanotechnology and drug resistance
|
Minko, Tamara
|
|
2013
|
136-137 |
13-14 |
p. 1665-1666
2 p.
|
artikel
|
| 21 |
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
|
Andrade, Fernanda
|
|
2013
|
136-137 |
13-14 |
p. 1816-1827
12 p.
|
artikel
|
| 22 |
Nanotechnology approaches for personalized treatment of multidrug resistant cancers
|
Minko, Tamara
|
|
2013
|
136-137 |
13-14 |
p. 1880-1895
16 p.
|
artikel
|
| 23 |
Nanotechnology as a therapeutic tool to combat microbial resistance
|
Pelgrift, Robert Y.
|
|
2013
|
136-137 |
13-14 |
p. 1803-1815
13 p.
|
artikel
|
| 24 |
Pathophysiological and pharmacological implications of mitochondria-targeted reactive oxygen species generation in astrocytes
|
Jou, Mei-Jie
|
|
2008
|
136-137 |
13-14 |
p. 1512-1526
15 p.
|
artikel
|
| 25 |
Pro-oxidant shift in glutathione redox state during aging
|
Rebrin, Igor
|
|
2008
|
136-137 |
13-14 |
p. 1545-1552
8 p.
|
artikel
|
| 26 |
Rationally designed nanovehicles to overcome cancer chemoresistance
|
Livney, Yoav D.
|
|
2013
|
136-137 |
13-14 |
p. 1716-1730
15 p.
|
artikel
|
| 27 |
Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor
|
Yin, Qi
|
|
2013
|
136-137 |
13-14 |
p. 1699-1715
17 p.
|
artikel
|
| 28 |
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
|
Sosnik, Alejandro
|
|
2013
|
136-137 |
13-14 |
p. 1828-1851
24 p.
|
artikel
|
| 29 |
Role of dichloroacetate in the treatment of genetic mitochondrial diseases
|
Stacpoole, Peter W.
|
|
2008
|
136-137 |
13-14 |
p. 1478-1487
10 p.
|
artikel
|
| 30 |
Role of integrated cancer nanomedicine in overcoming drug resistance
|
Iyer, Arun K.
|
|
2013
|
136-137 |
13-14 |
p. 1784-1802
19 p.
|
artikel
|
| 31 |
The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies
|
Tarnopolsky, M.A.
|
|
2008
|
136-137 |
13-14 |
p. 1561-1567
7 p.
|
artikel
|
Tijdschrift beschrijving